Abstract
The article presents the rationale for a new therapeutic strategy for treatment of patients with COVID-19, based on the combined use of biologic response modifiers and drugs targeting etiology and pathophysiology of the novel coronavirus infection, excluding disadvantages of polypharmacy, and providing a high clinical effect. This approach has been predominantly used in home health outpatient treatment of 324 patients with COVID-19 of variable severity using the biologic response modifiers “double drug cocktail” made of recombinant human interleukin-2 and recombinant human interferon alpha-2b in combination with alimemazine, nimesulide, rivaroxaban and antibiotic therapy (co-amoxiclav, or ceftriaxone) if secondary bacterial pneumonia was diagnosed. The results obtained indicate a dramatic improvement in the condition of patients, even with a severe COVID-19, which made possible to avoid artificial ventilation and prevent deaths.
Highlights
The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) led to occurrence of 181 521 067 COVID-19 cases and 3 937 437 global deaths as of 30 June 2021 [1]
We reviewed papers prepared by the World Health Organization (WHO) and National Institutes of Health (NIH) (USA)
319 patients received home health outpatient therapy of COVID-19: mild COVID-19 – 202 patients, moderate COVID-19 – 104 patients (75 patients with clinical symptoms of viral pneumonia: fever > 38 °C, chills, respiratory rate > 22 breaths / min, dyspnoea, nonproductive cough, rhinitis, myalgias, headaches, fatigue, but no signs of severe pneumonia; 29 patients with clinical symptoms of bacterial pneumonia: cough with mucus that is yellow, green, or tinged with blood, stitching chest pain in the that is worse when coughing or breathing and rigors), severe COVID-19 – 13 patients (clinical signs of bacterial pneumonia, respiratory rate > 30 breaths / min, volume lung lesions 55-72% according to computed tomography, blood saturation level (SpO2) 90-75%)
Summary
The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) led to occurrence of 181 521 067 COVID-19 cases and 3 937 437 global deaths as of 30 June 2021 [1]. The outcome of COVID-19 in each individual patient depends on the predominance of the mechanisms of etiopathogenesis (the onset and development of the disease) and sanogenesis (self-healing of the body) [5]. These mechanisms are closely related, but opposite in their biological orientation. It is logical to argue that a high therapeutic effect can be achieved with an etiopathogenetically and sanogenetically oriented approach to handling patients with COVID-19 In this regard, the following etiopathogenetic mechanisms of COVID-19 are of particular importance for the development of therapeutic strategies: direct viral toxicity, endotheliopathy, hypercoagulability, vasculitis, immune system dysregulation with non-specific hyperinflammatory state (cytokine storm), maladaptation of the angiotensin-converting enzyme-2 (ACE2) pathway [6], [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
